Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061919 | 0.77 | SCN9A (0.42) | MAOBMAOAHTR2AKCNH2SLC6A4 | |
| SCHEMBL366687 | 0.75 | SCN9A (0.50) | MAOBMAOAHTR2AKCNH2SLC6A4 | |
| SCHEMBL16059166 | 0.75 | SCN9A (0.48) | MAOBMAOAHTR2AKCNH2SLC6A4 | |
| SCHEMBL366085 | 0.72 | SCN9A (0.58) | SCN9A | |
| SCHEMBL30224701 | 0.71 | VCAM1 (0.48) | MAOBMAOAMRGPRX4L3MBTL1ALDH1A1 | |
| SCHEMBL559815 | 0.71 | VCAM1 (0.48) | MAOBMAOAMRGPRX4L3MBTL1ALDH1A1 | |
| SCHEMBL12111194 | 0.70 | PARP15 (0.47) | MAOBMAOAALDH1A1 | |
| SCHEMBL17289808 | 0.70 | MPO (0.39) | MAOBMAOAL3MBTL1 | |
| SCHEMBL13577185 | 0.69 | MAOB (0.49) | MAOBKCNH2MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL30765128 | 0.69 | NR4A2 (0.49) | MAOBMAOAMRGPRX4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | MAOB 3660/4885MAOA 3705/4885HTR2A 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.